drugset / Trial / NCT00512486

A Sequential Dose-Escalation Study in Subjects With Mild Asthma

NCT00512486

Phase 1 Completed 42 enrolled MedImmune LLC
Non-randomizedSingle-groupOpen-label

Summary

The primary objective of this study is to investigate the safety of administration of this drug by increasing doses to male and female adult subjects with mild asthma.

Timeline

Start
2006-11
Primary completion
2008-09
Completion
2008-10

Drugs

EvaluationDrugModalityDoseRoute
Comparator Benralizumab Monoclonal antibody 0.0003 mg/kg Intravenous
Comparator Benralizumab Monoclonal antibody 0.003 mg/kg Intravenous
Comparator Benralizumab Monoclonal antibody 0.03 mg/kg Intravenous
Comparator Benralizumab Monoclonal antibody 0.1 mg/kg Intravenous
Comparator Benralizumab Monoclonal antibody 0.3 mg/kg Intravenous
Comparator Benralizumab Monoclonal antibody 1 mg/kg Intravenous
Comparator Benralizumab Monoclonal antibody 3 mg/kg Intravenous

Indications